Search company, investor...

Founded Year

2006

Stage

Series C - VI | Alive

Total Raised

$43.44M

Last Raised

$10.3M | 1 mo ago

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+210 points in the past 30 days

About PRISM BioLab

PRISM BioLab is a biotechnology company that focuses on drug discovery. The company offers proprietary PepMetics Technology, a drug discovery platform that designs molecules to mimic certain types of peptides using unique, stable scaffolds. It was founded in 2006 and is based in Fujisawa, Japan.

Headquarters Location

Shonan Eye Park 2-26-1, Muraokahigashi

Fujisawa, 251-0012,

Japan

0466-53-8383

Loading...

Loading...

Expert Collections containing PRISM BioLab

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

PRISM BioLab is included in 1 Expert Collection, including Digital Health.

D

Digital Health

10,804 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

PRISM BioLab Patents

PRISM BioLab has filed 15 patents.

The 3 most popular patent topics include:

  • clusters of differentiation
  • lactams
  • nitrogen heterocycles
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/15/2016

6/28/2022

Clusters of differentiation, Immune system, Immunology, Cancer treatments, Transcription factors

Grant

Application Date

6/15/2016

Grant Date

6/28/2022

Title

Related Topics

Clusters of differentiation, Immune system, Immunology, Cancer treatments, Transcription factors

Status

Grant

Latest PRISM BioLab News

PRISM BioLab Raises 1.5 Billion Yen in Series C Funding

Jan 26, 2024

The round saw participation from Eli Lilly and Company and Santec Holdings Corporation. The company intends to use the funds to expand biology and screening capabilities and advance internal pipeline of PPI inhibitors. Led by CEO Dai Takehara, PRISM BioLab is a discovery and development biotechnology company utilizing proprietary PepMetics® technology to discover orally available small molecule inhibitors of protein-protein interaction (PPI) targets and transform lives of patients suffering from cancer, autoimmune, fibrosis and other diseases. PepMetics® are a class of small molecules that mimic three-dimensional structures of alpha-helix and beta-turn, the peptide structures commonly found in intracellular PPI interphases and receptor-ligand interactions. By combining proprietary chemistry, know-how around PPI targets and AI-supported design, its technology can deliver inhibitors of challenging PPI targets. The technology holds promise to expand the field of drug discovery by turning previously undruggable PPIs into targets readily druggable with small molecules and by generating oral small molecule alternatives for injectable biologics. FinSMEs

PRISM BioLab Frequently Asked Questions (FAQ)

  • When was PRISM BioLab founded?

    PRISM BioLab was founded in 2006.

  • Where is PRISM BioLab's headquarters?

    PRISM BioLab's headquarters is located at Shonan Eye Park, Fujisawa.

  • What is PRISM BioLab's latest funding round?

    PRISM BioLab's latest funding round is Series C - VI.

  • How much did PRISM BioLab raise?

    PRISM BioLab raised a total of $43.44M.

  • Who are the investors of PRISM BioLab?

    Investors of PRISM BioLab include Eli Lilly and Company, Santec Corporation, Eisai Innovation, DBJ Capital, Daiwa Corporate Investment and 14 more.

Loading...

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.